share_log

微創醫療：上海微創心脈醫療科技（集團）股份有限公司截至二零二三年十二月三十一日止十二個月經審核財務資料

MICROPORT: AUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE TWELVE MONTHS ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 27 09:09
Summary by Moomoo AI
微創醫疗科學有限公司（微創醫疗）旗下子公司上海微創心脈醫療科技（心脈醫療科技）公布了截至2023年12月31日止十二個月的經審核財務報告。報告顯示，心脈醫療科技的收入達到人民幣1,187,204.5千元，較上一年度的896,500.4千元增長32.43%。利潤總額和歸屬於心脈醫療科技股權持有人的淨利潤分別為人民幣572,267.0千元和492,432.0千元，年增率分別為38.26%和37.98%。總資產和歸屬於心脈醫療科技股權持有人的總權益分別增長至人民幣4,246,209.4千元和3,843,816.2千元，分別較去年同期增長112.83%和123.65%。微創醫疗持有心脈醫療科技40.32%的股權，其業績已綜合入微創醫疗的財務報表中。投資者在買賣微創醫疗證券時應注意，上述財務數據僅反映心脈醫療科技的業務表現，並非微創醫疗整體業務的全面情況。
微創醫疗科學有限公司（微創醫疗）旗下子公司上海微創心脈醫療科技（心脈醫療科技）公布了截至2023年12月31日止十二個月的經審核財務報告。報告顯示，心脈醫療科技的收入達到人民幣1,187,204.5千元，較上一年度的896,500.4千元增長32.43%。利潤總額和歸屬於心脈醫療科技股權持有人的淨利潤分別為人民幣572,267.0千元和492,432.0千元，年增率分別為38.26%和37.98%。總資產和歸屬於心脈醫療科技股權持有人的總權益分別增長至人民幣4,246,209.4千元和3,843,816.2千元，分別較去年同期增長112.83%和123.65%。微創醫疗持有心脈醫療科技40.32%的股權，其業績已綜合入微創醫疗的財務報表中。投資者在買賣微創醫疗證券時應注意，上述財務數據僅反映心脈醫療科技的業務表現，並非微創醫疗整體業務的全面情況。
Shanghai Micro-Chung Cardiac Medical Technology (Cardiac Medical Technology), a subsidiary of MicroChung Medical Sciences Co., Ltd. (Microchong Medical Technology), announced its audited financial statements for the twelve months ended December 31, 2023. The report showed that Cardiac Medical Technology revenue reached RMB1,187,204.5 thousand, an increase of 32.43% from the previous year's $896,500.4 thousand. Total profit and net profit attributable to Cardiac Medical Technology equity holders were RMB572,267.0 thousand and RMB492,432.0 thousand, respectively, with year-over-year growth of 38.26% and 37.98%, respectively. Total assets and total equity attributable to Cardiac Medical Technology equity holders increased to RMB4,246,209.4 thousand and RMB3,843,816.2 thousand, respectively, an increase of 112.83% and 123.65% over the same period last year. Microtech owns 40.32% of Cardiac Medical Technology, and its results are integrated into MicroVenture Medical's financial statements. Investors should note when buying and selling Microtech Medical Securities that the above financial data only reflects the performance of Cardiac Medical Technology and not the overall situation of MicroVenture Healthcare as a whole.
Shanghai Micro-Chung Cardiac Medical Technology (Cardiac Medical Technology), a subsidiary of MicroChung Medical Sciences Co., Ltd. (Microchong Medical Technology), announced its audited financial statements for the twelve months ended December 31, 2023. The report showed that Cardiac Medical Technology revenue reached RMB1,187,204.5 thousand, an increase of 32.43% from the previous year's $896,500.4 thousand. Total profit and net profit attributable to Cardiac Medical Technology equity holders were RMB572,267.0 thousand and RMB492,432.0 thousand, respectively, with year-over-year growth of 38.26% and 37.98%, respectively. Total assets and total equity attributable to Cardiac Medical Technology equity holders increased to RMB4,246,209.4 thousand and RMB3,843,816.2 thousand, respectively, an increase of 112.83% and 123.65% over the same period last year. Microtech owns 40.32% of Cardiac Medical Technology, and its results are integrated into MicroVenture Medical's financial statements. Investors should note when buying and selling Microtech Medical Securities that the above financial data only reflects the performance of Cardiac Medical Technology and not the overall situation of MicroVenture Healthcare as a whole.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more